Japanese subsidiary, Sosei Co., Ltd., has signed a distribution agreement with FUJIFILM Pharma Co., Ltd
for the commercialization of SO-1105 in Japan. SO-1105 is an antifungal agent, administered as a muco-adhesive buccal tablet for the treatment of oropharyngeal candidiasis in immunocompromised patients. The drug is currently registered in 24 European countries, in South Korea, and in the U.S., under the trade names Loramyc/Oravig. Sosei acquired exclusive development and commercialization rights to SO-1105 in Japan from BioAlliance Pharma in May 2011.
Sosei will be responsible for registration, manufacturing and supply, and FUJIFILM will be responsible for marketing and distribution of SO-1105. Sosei is eligible to receive a total of 900 million yen as an initial payment and development and regulatory milestones, as well as royalties on sales.